Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2017

01-02-2017 | Original Article

Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer

Published in: International Journal of Clinical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Our previous nonrandomized prospective study showed that template-based lymphadenectomy improved survival among patients with renal pelvic cancer but not among patients with ureteral cancer. However, regional node sites vary according to the tumor’s location in relation to the ureter. Therefore, this retrospective study examined the therapeutic role of lymphadenectomy for ureteral cancer according to tumor location.

Methods

Between January 1988 and September 2015, we performed nephroureterectomy for 154 patients with nonmetastatic urothelial carcinoma of the ureter at two Japanese institutions. The tumors’ locations were classified as the lower ureter or the upper/middle ureter (before the cranial crossing of the common iliac artery). The appropriate regional nodes were identified based on our previous mapping study. Dissection was classified as complete lymphadenectomy (all regional sites were dissected), incomplete lymphadenectomy (not all sites were dissected), or no lymphadenectomy. We focused the analyses on patients with ≥pT2 disease to clarify the effect of the lymphadenectomy.

Results

Among the 48 patients with upper/middle ureteral cancer, recurrence-free and cancer-specific survival were significantly higher in the complete lymphadenectomy group (vs. the incomplete or no lymphadenectomy groups). However, there were no differences in recurrence-free and cancer-specific survivals among the 56 patients with lower ureteral cancer. In the patients with upper/middle ureteral cancer, multivariate analysis revealed that template-based lymphadenectomy was independently associated with a reduced risk of cancer-specific mortality.

Conclusions

Template-based lymphadenectomy has a therapeutic benefit for treating patients with upper/middle ureteral cancer but not for treating patients with lower ureteral cancer.
Literature
1.
Oya M, Kikuchi E, Committee for Establishment of Clinical Practice Guideline for Management of Upper Tract Urothelial C et al (2015) Evidenced-based clinical practice guideline for upper tract urothelial carcinoma(summary-Japanese Urological Association, 2014 edition). Int J Urol 22:3–13CrossRefPubMed
2.
Rouprêt M, Babjuk M, Böhle A et al (2015) Guidelines on upper urinary tract urothelical cell carcinoma. Eur Assoc Urol, Arnhem
3.
Brausi MA, Gavioli M, De Luca G et al (2007) Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol 52:1414–1420CrossRefPubMed
4.
Kondo T, Nakazawa H, Ito F et al (2007) Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 178:1212–1217 (discussion 1217) CrossRefPubMed
5.
Roscigno M, Cozzarini C, Bertini R et al (2008) Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 53:794–802CrossRefPubMed
6.
Abe T, Shinohara N, Muranaka M et al (2010) Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes. Eur J Surg Oncol 36:1085–1091CrossRefPubMed
7.
Kondo T, Hara I, Takagi T et al (2014) Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol 21:453–459CrossRefPubMed
8.
Kondo T, Hara I, Takagi T et al (2014) Possible role of template-based lymphadenectomy in reducing the risk of regional node recurrence after nephroureterectomy in patients with renal pelvic cancer. Jpn J Clin Oncol 44:1233–1238CrossRefPubMed
9.
Kondo T, Nakazawa H, Ito F et al (2007) Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology 69:265–269CrossRefPubMed
10.
Kondo T, Tanabe K (2012) Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract. Int J Urol 19:710–721CrossRefPubMed
11.
Sobin LH, Gospodarpwicz MK, Wittekind CH. (2009) Renal plevis and ureter (ICD-O C65, C66). TNM classification of malignant tumors, 7th edn. Wiley-Liss, New York, pp 258–261
12.
Sagalowsky AI, Jarrett TW, Flanigan RC (2012) Urothelial tumors of the upper urinary tract and ureter. In: Wein AJ, Kavoussi LR, Novick AC et al (eds) Campbell-Walsh Urology, 10th edn. Saunders, New York, pp 1516–1553CrossRef
13.
Lughezzani G, Jeldres C, Isbarn H et al (2010) Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU Int 105:799–804CrossRefPubMed
14.
Burger M, Shariat SF, Fritsche HM et al (2011) No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. World J Urol 29:465–472CrossRefPubMed
15.
Mason RJ, Kassouf W, Bell DG et al (2012) The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology 79:840–845CrossRefPubMed
16.
Ouzzane A, Colin P, Ghoneim TP et al (2013) The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol 31:189–197CrossRefPubMed
17.
Roscigno M, Shariat SF, Margulis V et al (2009) The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 56:512–518CrossRefPubMed
18.
Kondo T, Tanabe K (2011) The role of lymph node dissection in the management of urothelial carcinoma of the upper urinary tract. Int J Clin Oncol 16:170–178CrossRefPubMed
19.
Matin SF, Sfakianos JP, Espiritu PN et al (2015) Patterns of lymphatic metastases in upper tract urothelial carcinoma and proposed dissection templates. J Urol 194:1567–1574CrossRefPubMedPubMedCentral
20.
Kondo T, Hashimoto Y, Kobayashi H et al (2010) Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol 17:848–854CrossRefPubMed
Metadata
Title
Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer
Publication date
01-02-2017
Published in
International Journal of Clinical Oncology / Issue 1/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1024-7

Other articles of this Issue 1/2017

International Journal of Clinical Oncology 1/2017 Go to the issue

Original Article

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy

Original Article

Psychological impact of positive cervical cancer screening results among Japanese women

Original Article

Estimation of Physiologic Ability and Surgical Stress (E-PASS) versus modified E-PASS for prediction of postoperative complications in elderly patients who undergo gastrectomy for gastric cancer

Original Article

Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma

Original Article

Nutritional care of cancer patients: a survey on patients’ needs and medical care in reality

Original Article

Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits